Octapharma AG

82 articles about Octapharma AG

• Octapharma AG Update: Product Withdrawal/Product Recall - Octagam(R)

  9/24/2010

• Octapharma AG Release: The Next-Generation VWF/FVIII Concentrate, Wilate(R), Strives to Reflect the Normal Physiological Condition

  9/16/2010

• Octapharma AG’s Drive to Prevent and Eradicate FVIII Antibody Inhibitors in Haemophilia Treatment

  9/13/2010

• New Octapharma AG 10% High Purity Immunoglobulin Enters Phase II/III Study in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

  9/8/2010

• Octapharma AG Release: Uniplas(R) Clinical Development Successfully Completed

  8/26/2010

• Octapharma AG Trial on Intravenous Immunoglobulin (IVIG) in Alzheimer's Disease at ICAD 2010 Congress

  4/19/2010

• Octapharma AG Results 2009

  3/22/2010

• Octapharma AG: New High Purity Immunoglobulin Enters Phase III in Europe and the US

  2/16/2010

• Octapharma AG Receives Orphan Drug Exclusivity Approval for wilate(R)

  1/13/2010

• Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market

  10/5/2009

• Octapharma AG Provides ProMetic BioSciences, Inc. With a $4.5 M Advance on a Long-Term Supply Agreement

  10/1/2009

• Octapharma AG Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies

  8/26/2009

• Octapharma AG Targeting the Major Risk of Hemophilia Treatment

  8/26/2009

• Octapharma AG Announces First-Ever Research Grants Program, Demonstrating Commitment to Cutting-Edge Clinical Research

  3/30/2009

• Octapharma AG Names Dennis D. Curtin To Lead U.S. Plasma Operations

  12/5/2008

• Octapharma AG Agrees to Acquire 33 Plasma Centers Throughout the U.S.

  8/5/2008

• ProMetic Life Sciences Inc. Announces Octapharma AG Publication of PRDT's Prion Removal Resin in Octaplas(R) Manufacturing Process

  6/10/2008

• ProMetic Life Sciences Inc. Announces Octapharma AG Publication of PRDT'S Prion Removal Resin in Octaplas(R)

  6/10/2008

• Haemonetics Corporation and Octapharma AG Announce Plasma Collection Technology Contract

  5/30/2008

• BAC and Octapharma AG to Develop Custom Ligand for Recombinant Plasma Protein

  3/13/2008